ID
15546
Description
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Please document clinically significant findings as Adverse Events. Clinical Significance is defined as any variation in physical findings that has medical relevance and may result in an alteration in medical care. Safety Blood and Urine Examinations: Please document the results for Serum Creatinine, Platelets and TSH on CRF-Pages "Safety Laboratory Assessments". Part: Relapse Evaluation Visit No. X, Please enter Number of Visit below
Link
https://clinicaltrials.gov/ct2/show/NCT02419378
Keywords
Versions (1)
- 6/2/16 6/2/16 -
Uploaded on
June 2, 2016
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Relapse Evaluation Visit No. X Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Relapse Evaluation Visit No. X Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
Similar models
Relapse Evaluation Visit No. X Vital Signs Multiple Sclerosis ALAIN01 NCT02419378
C0449438 (UMLS CUI [1,2])
C0449438 (UMLS CUI [1,2])
C0018793 (UMLS CUI [1,2])
C0018793 (UMLS CUI [1,2])
C0024109 (UMLS CUI [1,2])
C0024109 (UMLS CUI [1,2])
C0000726 (UMLS CUI [1,2])
C0000726 (UMLS CUI [1,2])
C0278454 (UMLS CUI [1,2])
C0022417 (UMLS CUI [1,3])
C0022417 (UMLS CUI [1,2])
C0278060 (UMLS CUI [1,2])
C0278060 (UMLS CUI [1,2])
C0031809 (UMLS CUI [1,2])
C1705848 (UMLS CUI [1,3])